Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 3

3(42.9%)

Phase 1

3(42.9%)

Phase 2

1(14.3%)

7Total

Phase 3(3)

Phase 1(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07335055Phase 2Recruiting

A Study for HSK47388 in Participants With Ulcerative Colitis

Role: collaborator

NCT07404306Phase 1Completed

Part 1: Dose-Finding of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users

Role: lead

NCT06795204Phase 1Completed

Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)

Role: lead

NCT05486416Phase 3Completed

Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery

Role: lead

NCT05478174Phase 3Completed

Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia

Role: lead

NCT04711837Phase 3Completed

Efficacy and Safety of HSK3486 Compared to Propofol in Induction of General Anesthesia in Adults Having Elective Surgery

Role: lead

NCT05614544Phase 1Completed

Dose-Finding and Human Abuse Potential Study Of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users

Role: lead

All 7 trials loaded